MAXIMUS, Inc. (NYSE:MMS) – Analysts at Jefferies Group boosted their Q2 2018 EPS estimates for shares of MAXIMUS in a research report issued to clients and investors on Thursday. Jefferies Group analyst D. Styblo now forecasts that the health services provider will post earnings of $0.83 per share for the quarter, up from their previous forecast of $0.77. Jefferies Group also issued estimates for MAXIMUS’s Q3 2018 earnings at $0.84 EPS, Q4 2018 earnings at $0.85 EPS and FY2019 earnings at $3.69 EPS.

A number of other analysts have also commented on MMS. Maxim Group reaffirmed a “hold” rating and issued a $69.00 target price (up from $66.00) on shares of MAXIMUS in a research report on Thursday, February 8th. Zacks Investment Research raised MAXIMUS from a “hold” rating to a “buy” rating and set a $71.00 target price for the company in a research report on Tuesday. Finally, Canaccord Genuity decreased their target price on MAXIMUS from $71.00 to $65.00 and set a “hold” rating for the company in a research report on Friday, February 9th. One research analyst has rated the stock with a sell rating, five have given a hold rating and one has issued a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus target price of $66.60.

Shares of MAXIMUS (MMS) opened at $65.34 on Monday. MAXIMUS has a 12-month low of $57.12 and a 12-month high of $72.71. The company has a market capitalization of $4,203.65, a PE ratio of 20.27, a P/E/G ratio of 2.14 and a beta of 1.21. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.57 and a quick ratio of 2.57.

MAXIMUS (NYSE:MMS) last issued its earnings results on Thursday, February 8th. The health services provider reported $0.78 EPS for the quarter, beating analysts’ consensus estimates of $0.77 by $0.01. MAXIMUS had a return on equity of 22.93% and a net margin of 8.99%. The business had revenue of $623.10 million during the quarter, compared to analyst estimates of $624.36 million. During the same period in the previous year, the company posted $0.71 EPS. The firm’s revenue was up 2.6% compared to the same quarter last year.

A number of hedge funds have recently added to or reduced their stakes in MMS. JPMorgan Chase & Co. boosted its stake in MAXIMUS by 459.2% during the 2nd quarter. JPMorgan Chase & Co. now owns 25,842 shares of the health services provider’s stock valued at $1,619,000 after purchasing an additional 21,221 shares during the last quarter. New York State Common Retirement Fund boosted its stake in MAXIMUS by 10.0% during the 2nd quarter. New York State Common Retirement Fund now owns 86,332 shares of the health services provider’s stock valued at $5,407,000 after purchasing an additional 7,815 shares during the last quarter. UBS Asset Management Americas Inc. boosted its stake in MAXIMUS by 1.7% during the 2nd quarter. UBS Asset Management Americas Inc. now owns 34,898 shares of the health services provider’s stock valued at $2,186,000 after purchasing an additional 592 shares during the last quarter. California Public Employees Retirement System boosted its stake in MAXIMUS by 2.7% during the 2nd quarter. California Public Employees Retirement System now owns 99,900 shares of the health services provider’s stock valued at $6,257,000 after purchasing an additional 2,600 shares during the last quarter. Finally, Voya Investment Management LLC boosted its stake in shares of MAXIMUS by 10.9% in the 2nd quarter. Voya Investment Management LLC now owns 29,734 shares of the health services provider’s stock worth $1,862,000 after buying an additional 2,932 shares during the last quarter. Institutional investors and hedge funds own 95.55% of the company’s stock.

In other MAXIMUS news, Director Russell A. Beliveau sold 1,000 shares of MAXIMUS stock in a transaction dated Tuesday, January 2nd. The stock was sold at an average price of $71.73, for a total transaction of $71,730.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, General Counsel David Francis sold 3,600 shares of MAXIMUS stock in a transaction dated Tuesday, February 13th. The shares were sold at an average price of $64.50, for a total value of $232,200.00. Following the transaction, the general counsel now owns 10,017 shares of the company’s stock, valued at approximately $646,096.50. The disclosure for this sale can be found here. Insiders have sold a total of 69,617 shares of company stock valued at $4,789,052 in the last quarter. Company insiders own 2.48% of the company’s stock.

The business also recently declared a quarterly dividend, which will be paid on Wednesday, February 28th. Shareholders of record on Thursday, February 15th will be paid a dividend of $0.045 per share. The ex-dividend date of this dividend is Wednesday, February 14th. This represents a $0.18 dividend on an annualized basis and a yield of 0.28%. MAXIMUS’s dividend payout ratio (DPR) is currently 5.36%.

WARNING: “Brokers Set Expectations for MAXIMUS, Inc.’s Q2 2018 Earnings (MMS)” was originally reported by TheOlympiaReport and is the property of of TheOlympiaReport. If you are viewing this piece of content on another domain, it was copied illegally and republished in violation of U.S. & international copyright laws. The legal version of this piece of content can be accessed at https://theolympiareport.com/2018/02/14/brokers-set-expectations-for-maximus-inc-s-q2-2018-earnings-mms.html.

MAXIMUS Company Profile

MAXIMUS, Inc provides business process services (BPS) to government health and human services agencies. The Company operates through three segments: U.S. Federal Services, Health Services and Human Services. The U.S. Federal Services segment provides BPS and program management for large government programs, independent health review and appeals services for both the United States Federal Government, and state-based programs and technology solutions for civilian federal programs.

Earnings History and Estimates for MAXIMUS (NYSE:MMS)

Receive News & Ratings for MAXIMUS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MAXIMUS and related companies with MarketBeat.com's FREE daily email newsletter.